Press Releases

Oncology Pharma, Inc. and Kalos Therapeutics (“Kalos”) announced  that the companies amended the terms of their collaboration to explore treatment opportunities of the COVID-19 virus, for the benefit of the most vulnerable cancer patients with cardiovascular issues and/or a weakened immune system. George Colberg, Chairman and CEO of Kalos Therapeutics, and Dr. Vijay Mahant, Chief Scientific Officer of Oncology Pharma, have proposed the investigation of  Kalos T

Alnylam Pharmaceuticals, Inc., and Dicerna Pharmaceuticals, Inc. , both leaders in the field of ribonucleic acid interference (RNAi) therapeutics, announced today the formation of a development and commercialization collaboration on investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin (A1AT) deficiency-associated liver disease (alpha-1 liver disease). In addition, the companies have completed a cross-license of their respective intellectual property for Alnylam’s l

Shenogen, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in China and beyond, today announced that it has entered into an exclusive collaboration and licensing agreement with Shanghai BioArdis Co., Ltd. and BioArdis LLC for the development and commercialization of BioArdis' novel FGFR4 (fibroblast growth factor receptor 4) kinase inhibitor, BIO-1262/SNG-203, either as monot

Today, Care Access Research, the leader in rapid development and management of high-performing clinical research sites, announced it is leading a validation trial in conjunction with the FDA for a new at-home COVID-19 test developed by a private genomics lab that manufactures DNA screening kits. The goal of this validation study is to evaluate the efficacy of the new at-home test for diagnosing COVID-19. Mailing simple testing kits directly to patients could help reduce visits to ov

Digital Science, a leading technology company serving emergent needs across the research sector, is pleased to announce a partnership with Beijing-based technology company Zhipu.AI to conduct data challenges and collaborate in building a COVID-19 information portal. Zhipu.AI, a spin-out from Tsinghua University, aims to build an advanced artificial intelligence engine that can support and empower the research and innovation sectors globally. The company focuses on solving the curren

Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc.  announced an expansion to their broad multi-target existing collaboration for the development and commercialization of RNAi therapeutics for infectious diseases, including SARS-CoV-2, the virus that causes the disease COVID-19. This expansion includes up to three additional targets focused on host factors for SARS-CoV-2, including ACE2 and TMPRSS2, both of which are considered critical for viral entry, with the potential for an a

Flexion Therapeutics, Inc. announced that it has entered into an exclusive license agreement with HK Tainuo and Jiangsu Tainuo (a subsidiary of China Shijiazhuang Pharmaceutical Co, Ltd.) for the development and commercialization of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in Greater China (consisting of mainland China, Hong Kong and Macau, and Taiwan). Under the terms of the agreement, HK Tainuo will pay Flexion an upfront payment of $10 million. Fl

REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, and Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, today announced a new exclusive, worldwide license agreement, extending the companies' existing gene therapy partnership.

OliX Pharmaceuticals, Inc. a leading developer of RNAi therapeutics, announced that the Company has signed an exclusive worldwide licensing agreement with AM Chemicals (AMC) for the rights to patents and know-how encompassing the technology to conjugate N-acetylgalactosamine (GalNAc) to OliX' asymmetric small interfering RNA (asiRNA) molecules for liver targeting.   Under the agreement, AMC will supply a selection of GalNAc-modified phosphoramidites and solid supports to Ol

Lonza announces the launch of the TheraPEAK™ SfAAV™ Medium, the first chemically defined, non-animal origin medium designed specifically for the production of Adeno Associated Virus (AAV) in Spodoptera Fuigiperda (Sf9) insect cells for gene therapy applications. The new high-performance medium accelerates cell growth, increases productivity, and reduces process variability and costs, expediting time-to-market for safe, scalable, life-saving gene therapies. The unique benefits of t